Our findings indicate that FOXL2 may serve as a HCC biomarker and a predictor of Lenvatinib sensitivity, warranting further investigation into its role in HCC and its clinical application in treatment decision-making. Here, FOXL2 is linked to hepatocellular carcinoma.